Two New Peptide Targets Identified for Cervical Cancer Vaccine Development | Research

The takeaway

Multi-omics analysis of 284 cervical cancer samples identified two peptides from the PCLO gene — SISRFTLEK and LSEAGHFFY — as promising neoantigen targets for cancer vaccine development.

284 tumor samples analyzed
Multi-omics analysis of this large cervical cancer cohort identified PCLO as a novel immunogenic target with two validated peptide candidates

What the researchers found

From 284 cervical cancer samples, researchers identified 30 highly mutated genes and narrowed these to seven (TTN, PRKDC, PCLO, MUC17, HUWE1, RYR2, and CREBBP) that positively correlated with immune cell infiltration into tumors. PCLO stood out because it showed higher protein expression in tumor tissue versus normal tissue, marking it as a potential tumor antigen.

Using computational prediction algorithms (NetMHCpan-4.0 and NetCTL-1.2), two PCLO-derived peptides — SISRFTLEK (PCLOL4169F) and LSEAGHFFY (PCLOA3000S) — achieved the highest predicted immunogenicity scores. These peptides were validated experimentally: they activated T cells in vivo (confirmed by flow cytometry and RT-PCR) and stimulated immune responses in patient-derived peripheral blood mononuclear cells with matching HLA types in ELISpot assays.

Why it matters

Cervical cancer remains a major global health burden, and while HPV vaccines prevent new infections, they don't help patients with existing tumors — especially HPV-negative cases. Identifying neoantigen peptides that the immune system can target opens the door to therapeutic vaccines that could treat established cervical cancers by directing T cells to attack tumor-specific mutations.

How the study worked

The study used a computational pipeline analyzing TCGA data from 284 cervical cancer samples across three levels: genomic (mutation frequency), transcriptomic (immune cell infiltration via RNA-seq), and proteomic (protein expression). High-frequency mutations in genes correlated with immune infiltration were used to predict MHC class I neoantigen peptides via NetMHCpan-4.0 and NetCTL-1.2 algorithms. Top candidates were synthesized and validated experimentally using flow cytometry, real-time PCR for T cell activation markers, and ELISpot assays with patient PBMCs.

What this study cannot tell us

The candidate neoantigens were identified primarily through computational analysis of TCGA data, and while experimentally validated, the validation was limited in scope. The study did not test whether these peptide vaccines could shrink tumors in animal models or clinical settings. The peptides bind specific HLA types, so they would only be effective in patients with matching immune profiles. Additionally, tumor heterogeneity means not all cervical cancers will carry PCLO mutations.

How to read the evidence

This is a computational discovery study with preliminary experimental validation. While the bioinformatics pipeline is rigorous and the peptides showed immunogenicity in laboratory assays, no in vivo tumor challenge or clinical data exists yet. The evidence is early-stage but scientifically sound for a target identification study.

When this study was published

Published in 2025, this is a very recent study at the forefront of neoantigen discovery for cervical cancer, reflecting the latest multi-omics and peptide prediction tools.

The bigger picture

Neoantigen-based personalized cancer vaccines are one of the most exciting frontiers in oncology, with early successes in melanoma and other cancers. This study extends the approach to cervical cancer, identifying peptide targets beyond HPV-derived antigens. As mRNA vaccine platforms (like those proven in COVID-19) make rapid peptide vaccine manufacturing feasible, discoveries like these could be quickly translated into clinical trials for personalized or shared neoantigen vaccines.

Questions still open

Can vaccines using these PCLO-derived peptides produce tumor regression in animal models of cervical cancer?
What proportion of cervical cancer patients have both PCLO mutations and compatible HLA types to benefit from this approach?
Would combining these neoantigen peptides with checkpoint inhibitors enhance their therapeutic effectiveness?

Common questions

What is a neoantigen and why is it important for cancer vaccines?

A neoantigen is a new protein fragment that appears on cancer cells due to mutations in their DNA. Because these mutations don't exist in normal cells, the immune system can potentially recognize neoantigens as foreign and attack the tumor. Neoantigen peptides are the specific short protein sequences that get displayed on the cancer cell surface by MHC molecules, flagging the cell for destruction by T cells. Identifying the right neoantigens is the key challenge in developing personalized cancer vaccines.

Why do researchers need targets beyond HPV for cervical cancer vaccines?

While most cervical cancers are driven by HPV, some tumors don't express HPV oncoproteins — meaning HPV-targeted therapies won't work for these patients. Even in HPV-positive cancers, the virus can evade immune detection. Neoantigen peptides from mutated genes like PCLO provide alternative targets that are specific to the cancer's own mutations, offering a complementary or backup strategy for immune-based treatment when HPV-targeted approaches aren't sufficient.

Read the original research

Identification of neoantigen epitopes in cervical cancer by multi-omics analysis.

European journal of medical research, 30(1), 763

View on PubMed ↗Publisher’s paper ↗

Citation

Yuan, Jing; Xu, Na; Gong, Xueqi; Ai, Jihui; Li, Kezhen; Han, Yingyan. (2025). Identification of neoantigen epitopes in cervical cancer by multi-omics analysis.. European journal of medical research, 30(1), 763. https://doi.org/10.1186/s40001-025-03036-x